Coherus Biosciences | CHRS - Cost Of Sales


Coherus Biosciences reported $2.65M in Cost of Sales for its fiscal quarter ending in March of 2025.





Cost Of Sales Change Date
AbbVie USD 4.55B 757M Dec/2025
Acadia Pharmaceuticals USD 26.22M 4.58M Dec/2025
Akebia Therapeutics USD 8.13M 2.41M Mar/2025
ALKERMES USD 46.21M 5.38M Dec/2025
Alnylam Pharmaceuticals USD 267.72M 67.57M Dec/2025
Amarin USD 16.89M 18.51M Mar/2025
Amgen USD 1.79B 128M Dec/2025
Baxter International USD 2.4B 512M Dec/2025
Biogen USD 810.1M 205.1M Sep/2025
BioMarin Pharmaceutical USD 161.56M 16.62M Dec/2025
Bristol-Myers Squibb USD 4.92B 657M Dec/2025
Coherus Biosciences USD 2.65M 31.2M Mar/2025
Eli Lilly USD 3.37B 363.7M Dec/2025
Fujifilm JPY 509.85B 19.73B Dec/2025
Gilead Sciences USD 1.62B 50M Dec/2025
Ironwood Pharmaceuticals USD 29.83M 560K Sep/2024
Merck USD 3.32B 531M Dec/2025
Myriad Genetics USD 61.9M 600K Sep/2025
Pacira USD 54.62M 6.02M Dec/2025
Perrigo USD 747.4M 81.2M Dec/2025
Pfizer USD 6.29B 2.12B Dec/2025
PTC Therapeutics USD 16.3M 7.02M Dec/2025
Regeneron Pharmaceuticals USD 584.6M 63M Dec/2025
Sarepta Therapeutics USD 399.38M 247.93M Dec/2025
Teva Pharmaceutical Industries USD 2.06B 120M Dec/2025
Vertex Pharmaceuticals USD 466M 51.2M Dec/2025
Xencor USD 61.66M 50.95M Jun/2025
Zoetis USD 743M 60M Dec/2025